Market Access · Pharma
Pharma Market Access
Pharma market access is the work of turning evidence into reimbursement, so a medicine reaches the patients who need it at a price payers will fund.
The evidence that unlocks access, and the leaders who generate it, come together at RWE Connect 2026 in Boston.
Free. Instant download. No obligation.
What it involves
The Building Blocks of Pharma Market Access
Market access is not a single step but a set of connected disciplines, each shaping whether a medicine gets funded.
The journey
From Evidence to Reimbursement
Access is earned across the product lifecycle, long before launch and long after it. This is the path a medicine travels.
The evidence behind every step draws on HEOR and real-world evidence.
Who decides
The Payers and Decision-Makers
Access depends on convincing the people and bodies that control the budget. They differ by market, but the goal is the same.
The RWE connection
How Evidence Drives Access
Payers fund value, and value has to be proven. Real-world evidence has become one of the strongest arguments in the access toolkit, a core theme at RWE Connect 2026.
The hard part
Access Challenges Pharma Faces
Securing and keeping access has never been harder. These are the pressures every access team is working against.
The direction of travel
Where Pharma Market Access Is Heading in 2026
The rules of access are being rewritten by new evidence standards, pricing reform and value-based models. These are the forces on the agenda at RWE Connect 2026.
Who is in the room
Who Attends RWE Connect 2026
A senior, focused audience of the people who own evidence, value and access.
Seniority is confirmed: 150+ attendees, around 60% at Director or VP level and above. The functional mix shown is indicative; confirmed registration splits are shared with sponsors from the live delegate list.
Explore
Explore Related Topics
Market access sits at the meeting point of evidence, economics and payer strategy.
Sponsor RWE Connect 2026
Meet the Market Access Decision-Makers in Boston
The HEOR, market access and payer-strategy leaders who turn evidence into reimbursement gather at RWE Connect 2026: 150+ attendees, around 60% at Director or VP level and above.
RWE Connect 2026
Get the RWE Pipeline Report 2026
See the evidence trends reshaping pricing, reimbursement and access, then meet the people driving them in Boston.
- How RWE is changing access decisions
- What payers now expect from evidence
- Where value-based access is heading
Free. Instant download. No obligation.
Pharma Market Access: Common Questions
What is pharma market access?
Pharma market access is the work of securing coverage, reimbursement and appropriate use for a medicine, so the patients who need it can get it at a price payers will fund. It runs from early value planning through post-launch access.
Why does pharma market access matter?
A medicine only reaches patients if payers agree to fund it. Market access turns clinical and economic evidence into coverage and reimbursement, and it increasingly decides commercial success as much as approval does.
How is pharma market access different from market access in general?
Market access is the broad discipline of securing reimbursement. Pharma market access applies it to medicines specifically, across the product lifecycle from early evidence planning to launch and post-launch renewal.
What is the pharma market access journey?
Early value planning, evidence generation, pricing and positioning, HTA and payer submission, negotiation and reimbursement, and post-launch access and renewal.
Who are the payers and decision-makers?
National and regional payers, HTA bodies, pharmacy benefit managers in the US, hospital and formulary committees, and integrated health systems.
How does real-world evidence drive market access?
Real-world evidence shows how a medicine performs in practice, supports value and budget-impact arguments, and increasingly underpins HTA submissions and value-based agreements.
What is a value proposition in market access?
A clear, evidence-backed statement of the clinical, economic and patient value a medicine offers, tailored to what each payer needs to justify funding it.
What is a value-based agreement?
A contract that ties payment for a medicine to the outcomes it delivers in the real world, sharing risk between the manufacturer and the payer.
What challenges does pharma market access face?
Pricing pressure, rising evidence expectations, divergent HTA requirements across markets, payer skepticism, launch sequencing decisions, and post-launch reassessment.
How does HTA fit into market access?
Health technology assessment evaluates a medicine’s value to inform funding. A strong HTA outcome is often the gateway to reimbursement in many markets.
What is RWE Connect 2026?
RWE Connect 2026 is a two-day real-world evidence summit in Boston bringing together the RWE, HEOR and market access leaders who generate and apply real-world evidence, with 40+ speakers and 150+ attendees.
When and where is RWE Connect 2026?
14 to 15 October 2026 at the Hampton Inn by Hilton, Boston Seaport District, Boston, MA.
